A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Rhythm
- 23 Jul 2018 Status changed from recruiting to active, no longer recruiting, as reported in a Rhythm Pharmaceuticals media release.
- 14 Jun 2018 According to a Rhythm Pharmaceuticals media release, the company expects to report initial data from this trial in the third quarter of 2019.
- 14 Jun 2018 According to a Rhythm Pharmaceuticals media release, enrollment of the pivotal cohort of 10 patients has been completed in this trial.